Purdue Pharma Just Settled a Major Lawsuit in Oklahoma for $270 Million

Ticker

Monika Bauerlein,
CEO

Dear Reader,

The next few months are make-or-break for Mother Jones’ fundraising, and we need more online readers to pitch in than have been of late. In "It's Not a Crisis. This Is the New Normal," we take a level-headed look at the brutal economics of journalism, why investigative reporting like you get from us matters, and why we're optimistic we can grow our base of support in a big way—starting with hitting a huge $300,000 goal in just three weeks. Please learn more and donate if you can right now.

The next few months are make-or-break for Mother Jones’ fundraising. We need to raise $300,000 quickly, and we need more online readers to pitch in than have been. Please learn more in "It's Not a Crisis. This Is the New Normal," where we go into the brutal economics of journalism, and what makes Mother Jones unique and worth supporting if you can right now.

Toby Talbot/A

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.

Purdue Pharma, maker of OxyContin, will pay $270 million to settle a case brought by the Oklahoma Attorney General for helping to lay the groundwork of America’s opioid epidemic. The settlement, announced Tuesday, comes two months before the scheduled start of a televised trial.

The bulk of settlement money will fund a nearly $200 million endowment at Oklahoma State University’s Center for Wellness and Recovery, which will treat “the ongoing addiction epidemic nationwide,” according to a statement from state Attorney General Mike Hunter’s office. In addition, the Sackler family, which is not listed as a defendant in the lawsuit, pledged a $75 million donation to the center on Tuesday.

Only $12.5 million of the settlement—less than 5 percent of the funding—will directly address the epidemic’s ongoing effects in Oklahoma’s cities and counties. Last year, more than 3,000 Oklahomans were admitted to the hospital for non-fatal overdoses; each year, roughly 700 residents die of overdoses.

This marks the first settlement in a flood of more than 1,000 lawsuits brought against the company in recent years by state and local governments for its role in the opioid epidemic, which included heavily marketing OxyContin and misleading regulators, doctors, and patients about the pills’ addictive qualities. The settlement means that the public will not hear details of how the company promoted the addictive pills to doctors and patients. The next possibility for exposure of those tactics may come this fall, when multi-district litigation consolidating dozens of lawsuits from across the country is set to go to trial in Ohio.

Purdue officials acknowledged earlier this month that they were considering filing for bankruptcy because of the wave of lawsuits. Declaring bankruptcy doesn’t necessarily the mean the company would go out of business; it could use bankruptcy as a tool to consolidate the lawsuits it faces and cap the amount of damages it might have to pay.

Purdue has settled previous cases over the years for lesser amounts, including a $10 million West Virginia settlement in 2004. And in 2007, three company executives pleaded guilty to criminal charges for misbranding the narcotic.

Note: This article has been updated.